**Partial rescheduling of state-licensed medical marijuana and FDA-approved products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** An expedited DEA administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III ran from June 29 to July 15, 2026, but no final rule has been issued as of mid-August. Trader odds reflect uncertainty over the remaining rulemaking timeline, with the market assigning the highest probability to completion by year-end. Key variables include the DEA administrator’s final determination, any procedural delays or challenges, and administration priorities on implementation. Historical precedents for controlled-substance rescheduling show that final rules can follow hearings within weeks to months, though outcomes remain subject to administrative and legal processes.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於$796,329 交易量
2026-03-31
9月30日
14%
12月31日
29%
$796,329 交易量
9月30日
$0 交易量
14%
12月31日
$186,758 交易量
29%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of state-licensed medical marijuana and FDA-approved products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** An expedited DEA administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III ran from June 29 to July 15, 2026, but no final rule has been issued as of mid-August. Trader odds reflect uncertainty over the remaining rulemaking timeline, with the market assigning the highest probability to completion by year-end. Key variables include the DEA administrator’s final determination, any procedural delays or challenges, and administration priorities on implementation. Historical precedents for controlled-substance rescheduling show that final rules can follow hearings within weeks to months, though outcomes remain subject to administrative and legal processes.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
市場開放時間： Feb 7, 2026, 5:04 PM ET
交易量
$796,329結束日期
2026-03-31市場開放時間
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of state-licensed medical marijuana and FDA-approved products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** An expedited DEA administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III ran from June 29 to July 15, 2026, but no final rule has been issued as of mid-August. Trader odds reflect uncertainty over the remaining rulemaking timeline, with the market assigning the highest probability to completion by year-end. Key variables include the DEA administrator’s final determination, any procedural delays or challenges, and administration priorities on implementation. Historical precedents for controlled-substance rescheduling show that final rules can follow hearings within weeks to months, though outcomes remain subject to administrative and legal processes.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
交易量
$796,329結束日期
2026-03-31市場開放時間
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Partial rescheduling of state-licensed medical marijuana and FDA-approved products to Schedule III took effect in late April 2026 following a December 2025 executive order directing expedited action.** An expedited DEA administrative hearing on broader rescheduling of all marijuana from Schedule I to Schedule III ran from June 29 to July 15, 2026, but no final rule has been issued as of mid-August. Trader odds reflect uncertainty over the remaining rulemaking timeline, with the market assigning the highest probability to completion by year-end. Key variables include the DEA administrator’s final determination, any procedural delays or challenges, and administration priorities on implementation. Historical precedents for controlled-substance rescheduling show that final rules can follow hearings within weeks to months, though outcomes remain subject to administrative and legal processes.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions